Vistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Me
Go back to Vistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Me| (NASDAQ: VTGN) | Delayed: 0.63 -0.01 (1.56%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.64 | 52 Week High | $4.60 | |||
| Open | $0.65 | 52 Week Low | $2.81 | |||
| Day High | $0.69 | P/E | N/A | |||
| Day Low | $0.61 | EPS | $0.00 | |||
| Volume | 900,387 | |||||
